Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Mov Disord. 2010 Sep 15;25(12):1818-22. doi: 10.1002/mds.23191.
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.
我们在两项大型前瞻性队列研究中调查了钙通道阻滞剂（CCB）的使用是否与帕金森病（PD）风险降低相关：护士健康研究（NHS）和健康专业人员随访研究（HPFS）。使用 Cox 比例风险模型来估计相对风险（RR）和 95％置信区间（CI），以评估使用 CCB 与 PD 风险之间的关联，并在调整潜在混杂因素后进行评估。我们在随访期间确定了 514 例 PD 新发病例。在基线时使用 CCB（RR = 1.18，95％CI：0.73-1.92）、使用 CCB 的频率或使用 CCB 的持续时间与 PD 风险之间没有关联（所有 P > 0.2）。这些发现不支持 CCB 在提供神经保护以预防 PD 发展方面的作用。
